Literature DB >> 23229417

Three-dimensional endovaginal ultrasound examination following injection of Macroplastique for stress urinary incontinence: outcomes based on location and periurethral distribution of the bulking agent.

Aparna Hegde1, Aimee L Smith, Vivian C Aguilar, G Willy Davila.   

Abstract

INTRODUCTION AND HYPOTHESIS: Our aim was to use three-dimensional enodovaginal ultrasound (3D EVUS) to identify sonographic parameters that are associated with successful outcomes following injection of Macroplastique.
METHODS: Three hundred and sixty degree 3D EVUS was performed in 100 treatment-naïve patients following Macroplastique injection. The location, volumes, periurethral distribution, and distance of the hyperechoic densities from the urethrovesical junction were assessed. The patients were divided into two groups: group A (n = 72): patients who had good clinical outcome and group B (n = 28): patients who were not improved or worsened. The two groups were compared with respect to the ultrasound parameters measured.
RESULTS: Group A had a greater proportion of women with Macroplastique located in the proximal urethra, while midurethral location was found to be significantly more frequent in group B (p = 0.036). The odds of a circumferential periurethral distribution in group A were 13.62 times the odds in group B (95% CI: 5.12-56.95). When the location of the injection and the type of periurethral distribution were considered together, it was found that when the site of injection was proximal, the odds of circumferential distribution in group A was significantly greater than those in group B (odds ratio [95% CI]: 22 [3.05-203.49]; p < 0.001).
CONCLUSION: Proximally located Macroplastique and circumferential periurethral distribution of Macroplastique are individually associated with successful outcomes following the injection. The combination of circumferentially distributed and proximally located Macroplastique is associated with the best short-term clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229417     DOI: 10.1007/s00192-012-1983-9

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  26 in total

Review 1.  Stress incontinence injection therapy: what is best for our patients?

Authors:  Christopher R Chapple; Alan J Wein; Linda Brubaker; Roger Dmochowski; Montserrat Espuña Pons; François Haab; Simon Hill
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

2.  Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.

Authors:  José Tadeu Nunes Tamanini; Carlos Arturo Levi D'Ancona; Nelson Rodrigues Netto
Journal:  J Endourol       Date:  2006-12       Impact factor: 2.942

3.  Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically.

Authors:  Deborah Lightner; Eric Rovner; Jacques Corcos; Christopher Payne; Linda Brubaker; Harold Drutz; Gary Steinhoff
Journal:  Urology       Date:  2009-08-05       Impact factor: 2.649

4.  Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial.

Authors:  Christopher F Maher; Barry A O'Reilly; Peter L Dwyer; Marcus P Carey; Anne Cornish; Philip Schluter
Journal:  BJOG       Date:  2005-06       Impact factor: 6.531

5.  Imaging the urethral sphincter with three-dimensional ultrasound.

Authors:  S Athanasiou; V Khullar; K Boos; S Salvatore; L Cardozo
Journal:  Obstet Gynecol       Date:  1999-08       Impact factor: 7.661

Review 6.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.

Authors:  Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer
Journal:  Int Urogynecol J       Date:  2009-11-25       Impact factor: 2.894

7.  Macroplastique implantation system for the treatment of female stress urinary incontinence.

Authors:  José Tadeu Nunes Tamanini; Carlos Arturo Levi D'Ancona; Valdir Tadini; Nelson Rodrigues Netto
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

8.  Three-dimensional ultrasonography: an objective outcome tool to assess collagen distribution in women with stress urinary incontinence.

Authors:  Gina A Defreitas; Tracey S Wilson; Philippe E Zimmern; Thalia B Forte
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

9.  Effects of Macroplastique Implantation System for stress urinary incontinence and urethral hypermobility in women.

Authors:  Ph H ter Meulen; L C M Berghmans; F H M Nieman; Ph E V A van Kerrebroeck
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-10-21

10.  Nonsurgical outpatient therapies for the management of female stress urinary incontinence: long-term effectiveness and durability.

Authors:  G Willy Davila
Journal:  Adv Urol       Date:  2011-06-23
View more
  1 in total

1.  Imaging findings of vinyl dimethyl polydimethylsiloxane used as a paraurethral injectable for female stress urinary incontinence.

Authors:  Allert M de Vries; Fenne M Casteleijn; Jan-Paul W R Roovers; John P F A Heesakkers; Jurgen J Fütterer
Journal:  Ther Adv Urol       Date:  2021-12-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.